Drugs / CIFURTILIMAB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02376699 | Feb 2015 → Mar 2023 | Hodgkins lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, head and neck squamous cell carcinoma +4 | Seagen Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT04993677 | Oct 2021 → Jan 2024 | melanoma, non-small cell lung carcinoma | Seagen Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CIFURTILIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095112 ↗ |
| Known as | SEA-CD40 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04993677 ↗ |
| Action | Activate | “activates CD40” PMID 37385724 ↗ Jun 2023 |
| Modality | Monoclonal antibody | “SEA-CD40 is an investigational, non-fucosylated, humanized monoclonal IgG1 antibody” PMID 37385724 ↗ Jun 2023 |
| Route | Intravenous | “SEA-CD40 was administered intravenously to patients with solid tumors or lymphoma” PMID 37385724 ↗ Jun 2023 |